Aragon Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• ADT (Standard of Care) · Oncology
  ADT (Androgen Deprivation Therapy) suppresses testosterone production or blocks androgen receptor signaling to inhibit growth of androgen-dependent prostate cancer cells.

Phase 2 pipeline

• ARN-509 · Oncology
  ARN-509 is an androgen receptor inhibitor.

Phase 1 pipeline

• JNJ 56021927
• JNJ-56021927 capsule
• JNJ-56021927 Softgel Capsule

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Aragon Pharmaceuticals, Inc. portfolio CI brief
• Aragon Pharmaceuticals, Inc. pipeline updates RSS